4Bone ND, Roger C. Risk distributions of 519 ICU admission for sepsis according to the definition of SIRS[J].Chest, 1992,101:1481 - 1483.
5Ntinha N, Pessegueiro H,Barros H.Serum hyaluronsn as a marker of liver fibrosis in asymptomatic chronic viral hepstitis B [ J ]. Scan J Clin Lab Invest, 1999,59:343 - 348.
6Ogata T, Okuda K, Ueno T, et al, Serum hyahuronan as a predictor of hepatic regeneration after hepatectomy in humans[ J ]. Eur J Clin Invest,1999.29:81 - 86.
7De Maio A, De Mooney M L, Matesic L E, et al. Genetic component in the in.flammtory response induced by bacterial lipopolysaccharide[J] .Shock,1998,10:319 - 323.
8黎鳌，现代创伤学，1996年，108页
9Smith RP, Lipworth BJ. C-reactive protein in simple community- acquired pneumonia[J]. Chest, 1995, 107 (4):1028-1032.
6Rabe KF,Hurd S,Anzueto A,et al.Global strategy for the diagnosis,management,and p revention of chronic obstructive pulmoary disease:GOLD executive summary[J].Am J Respir Crit CareMed,2007,176 (6):532.
7Philippe A,Ariane B,Aurélia R.SAPS Ⅱ revisited[J].Intensive Care Med,2005,31 (4):416-423.
8Cunningham LL,Madsen MJ,Van Sickels JE.Using prealbumin as an in-Flammatory marker for patients withdeep space infections of odontogenic origin[J].OralMaxillofacial Surg,2006,64(3):375-378.
9American Thoracic Society Documents.Guidelines for the manage- ment of adults with hospital-acquied, ventil ator-associated and heathcare-associated pneumonia[J].Am J Respir Critcare Med,2005, 171(4) :388.
10Philippe A,Ariane B,Aurelia R.SAPS Ⅱ revisited[J].Intensive Care Med,2005,31 (4) :416.
